ASCO 2022 | Pfizer Información Médica

La información de esta página es seleccionada de materiales de congresos, áreas terapéuticas y de enfermedades. No pretende servir como una descripción general completa de todos los contenidos mencionados

Volver a Congresos

Póster

Shore N, Powles TB, Bedke J, Galsky MD, Kopyltsov E, Necchi A, Palou Redorta J, Vermette JJ, Randall AE, Pierce KJ, Cesari R, Steinberg GD Junio 4, 2022 ASCO 2022 Cáncer Urotelial

A Phase 3 Study of the Subcutaneous Programmed Cell Death Protein 1 Inhibitor Sasanlimab as Single Agent for Patients with Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer: CREST Study Cohort B

Ver Presentación Ver resumen en lenguaje sencillo

Póster

Valderrama BP, Powles T, Sridhar SS, Caserta C, Loriot Y, Gupta S, Bellmunt J, Sternberg CN, Wang J, Costa N, Laliberte RJ, di Pietro A, Park SH, Grivas P Junio 4, 2022 ASCO 2022 Cáncer Urotelial

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes From JAVELIN Bladder 100 in Subgroups Defined by Response to First-Line Chemotherapy

Ver Presentación Ver resumen en lenguaje sencillo

Póster

Cortes JE, Milojkovic D, Gambacorti-Passerini C, García-Gutiérrez V, Mauro MJ, Leip E, Purcell S, Viqueira A, Brümmendorf TH Junio 4, 2022 ASCO 2022 Hematología

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia: Gastrointestinal, Liver, Effusion and Renal Safety Characterization in the BFORE Trial

Ver Presentación Ver resumen en lenguaje sencillo

Póster

Jakubowiak A, Bahlis NJ, Raje NS, Costello CL, Dholaria B, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Chu MP, Gasparetto C, Dalovisio A, Sebag M, Lesokhin AM Junio 4, 2022 ASCO 2022 Hematología

Elranatamab, a BCMA-Targeted T-Cell Redirecting Immunotherapy, for Patients with Relapsed or Refractory Multiple Myeloma: Results from MagnetisMM-1

Ver Presentación Ver resumen en lenguaje sencillo

Póster

Liu FX, Costantino H, Ike C, Gupta S, Bhanegaonkar A, Thakkar S, Devgan G, Katzenstein H Junio 4, 2022 ASCO 2022 Cáncer Urotelial

Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): The US Physician PARADIGM Study (part 2)

Ver Presentación

Póster

Bellmunt J, Powles T, Climent Duran MA, Sridhar SS, Gurney H, Costa N, di Pietro A, Huang B, Gupta S, Grivas P Junio 4, 2022 ASCO 2022 Cáncer Urotelial

Long-Term Outcomes in Patients With Advanced Urothelial Carcinoma who Received Avelumab First-Line Maintenance With or Without Second-Line Treatment: Exploratory Analyses From JAVELIN Bladder 100

Ver Presentación Ver resumen en lenguaje sencillo

Póster

Grosicki S, Crafoord J, Koh Y, White D, Mellqvist U-H, Leip E, Kudla A, Finn G, Pruchniewski Ł Junio 4, 2022 ASCO 2022 Hematología

MagnetisMM-5: An Open-Label, Multicenter, Randomized Phase 3 Study of Elranatamab as Monotherapy and in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Ver Presentación Ver resumen en lenguaje sencillo

Póster

Fonseca R, Kuroda J, Ishida T, Popat R, Huang JSY, Yver A, Vandendries E, Elmeliegy M, Ma WD, Sborov DW Junio 4, 2022 ASCO 2022 Hematología

MagnetisMM-9: An Open-Label, Multicenter, Non-Randomized Phase 1/2 Study of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma

Ver Presentación Ver resumen en lenguaje sencillo

Presentación Oral

Finn RS, Rugo HS, Dieras V, Harbeck N, Im S-A, Gelmon KA, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Slamon DJ Junio 4, 2022 ASCO 2022 Cáncer de Mama

Overall Survival (OS) With First-Line Palbociclib Plus Letrozole (PAL+LET) Versus Placebo Plus Letrozole (PBO+LET) in Women with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (ER+/HER2− ABC): Analyses From PALOMA-2

Ver Presentación Ver resumen en lenguaje sencillo

Póster

Kopetz S, Bekaii-Saab T, Yoshino T, Chung C-H, Zhang X, Tabernero J Junio 4, 2022 ASCO 2022 Cáncer Colorectal

SEAMARK: Randomized Phase 2 Study of Pembrolizumab + Encorafenib + Cetuximab vs Pembrolizumab Alone for First-Line Treatment of BRAF V600E-Mutant Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Metastatic Colorectal Cancer (mCRC)

Ver Presentación Ver resumen en lenguaje sencillo

Materiales de Congresos

Materiales de Congresos

A Phase 3 Study of the Subcutaneous Programmed Cell Death Protein 1 Inhibitor Sasanlimab as Single Agent for Patients with Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer: CREST Study Cohort B

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes From JAVELIN Bladder 100 in Subgroups Defined by Response to First-Line Chemotherapy

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia: Gastrointestinal, Liver, Effusion and Renal Safety Characterization in the BFORE Trial

Elranatamab, a BCMA-Targeted T-Cell Redirecting Immunotherapy, for Patients with Relapsed or Refractory Multiple Myeloma: Results from MagnetisMM-1

Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): The US Physician PARADIGM Study (part 2)

Long-Term Outcomes in Patients With Advanced Urothelial Carcinoma who Received Avelumab First-Line Maintenance With or Without Second-Line Treatment: Exploratory Analyses From JAVELIN Bladder 100

MagnetisMM-5: An Open-Label, Multicenter, Randomized Phase 3 Study of Elranatamab as Monotherapy and in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

MagnetisMM-9: An Open-Label, Multicenter, Non-Randomized Phase 1/2 Study of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma

Overall Survival (OS) With First-Line Palbociclib Plus Letrozole (PAL+LET) Versus Placebo Plus Letrozole (PBO+LET) in Women with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (ER+/HER2− ABC): Analyses From PALOMA-2

SEAMARK: Randomized Phase 2 Study of Pembrolizumab + Encorafenib + Cetuximab vs Pembrolizumab Alone for First-Line Treatment of BRAF V600E-Mutant Microsatellite Instability-High (MSI-H)/Mismatch Repair-Deficient (dMMR) Metastatic Colorectal Cancer (mCRC)